Late-Onset Neutropenia After Rituximab-Containing Therapy for Non-Hodgkin Lymphoma

Micro-Abstract The incidence of late-onset neutropenia resulting from rituximab among 183 patients with non-Hodgkin lymphoma was 6% (13 episodes in 11 patients). The median time to onset of neutropenia was 75 days, and the median duration was 100 days. Although infectious complications were uncommon...

Full description

Saved in:
Bibliographic Details
Published in:Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2015-12, Vol.15 (12), p.761-765
Main Authors: Aguiar-Bujanda, David, Blanco-Sánchez, María Jesús, Hernández-Sosa, María, Galván-Ruíz, Saray, Hernández-Sarmiento, Samuel, Saura-Grau, Salvador, Bohn-Sarmiento, Uriel
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Anti-CD20
Anticancer therapy
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Chemoimmunotherapy
Female
Haematological toxicity
Hematology, Oncology and Palliative Medicine
Humans
Lymphoma, Non-Hodgkin - drug therapy
Male
Middle Aged
Neutropenia - chemically induced
Retrospective Studies
Rituximab - adverse effects
Rituximab - therapeutic use
Secondary effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Micro-Abstract The incidence of late-onset neutropenia resulting from rituximab among 183 patients with non-Hodgkin lymphoma was 6% (13 episodes in 11 patients). The median time to onset of neutropenia was 75 days, and the median duration was 100 days. Although infectious complications were uncommon, early recognition is required to avoid life-threatening complications.
ISSN:2152-2650
2152-2669
DOI:10.1016/j.clml.2015.07.635